Neurophet Secures FDA 510(k) Clearance for "Neurophet AQUA AD Plus," Marking Its Third U.S. Regulatory Milestone
Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based Alzheimer's disease imaging analysis Advanced analysis of neuroimaging features associated with cerebral microbleeds and edema supports...
Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with 'Neurophet AQUA'
New features include advanced analysis of multiple sclerosis (MS) and white matter hyperintensities alongside brain atrophy analysis Accelerating global expansion with cutting-edge technology targeting MS, a prevalent condition in North America and...